CV: Richard D Shell MD

Richard D Shell, MD
Clinical Associate Professor of Pediatrics
College of Medicine
The Ohio State University

Answers questions in the following forums:

Cystic Fibrosis

Practice Address:

Pulmonary Medicine
700 Children's Dr.
Columbus , OH 43205
(614) 722-4767

Education:

1996 - 1999. Fellow, Pediatric Pulmonology, Children’s Hospital and The Ohio State University, Columbus, Ohio
1993 - 1996. Pediatric Internship and Residency, Children’s Hospital and The Ohio State University Columbus, Ohio
1989 - 1993. M.D., 1993. The Medical College of Ohio (The Medical University of Ohio), Toledo, Ohio
1985 - 1989. B.A., Psychology and Art History, 1989, Washington University, St. Louis, Missouri

Licensure or Certification:

2002. Pediatric Board Renewal Certification through 2010
2002. Sub-Board Pediatric Pulmonology
2002 - Present. Pediatric Advanced Life Support
1997. American Board of Pediatrics
1996 - Present. The State Medical Board of Ohio
1994. National Board of Medical Examiners

Associations:

American Medical Association
American Academy of Pediatrics
American College of Chest Physicians
Ohio Thoracic Society
American Thoracic Society

Affiliations:

2006. Associate Director, Pediatric Clerkship, Department of Pediatrics, The Ohio State University
2002-Present. Associate Director, Cystic Fibrosis Clinic, Columbus Children’s Hospital
1999-Present. Assistant Professor of Pediatrics, Department of Pediatric Pulmonology, Children’s Hospital and The Ohio State University, Columbus, Ohio
1993 - 1999. Clinical Instructor, Pediatrics Children’s Hospital and The Ohio State University, Columbus, Ohio
Co-Investigator/Deputy Director, American Lung Association, Asthma Clinical Research Center

Partial List of Publications:

Shell,R. Preparing for a New Sibling. Columbus Parent Supplement to The Columbus Dispatch, September, 2006.
Chen, C, Jensen, R, Schnepp, B, Connell, M, Shell, R, Sferra, T, Bartlett, J, Clark, KR, Johnson, P. Molecular Characterization of Adeno-Associated Viruses in Children. Submitted: Journal of Virology, 2005.
Shell, R, Carpenter, J, Hong, S, McCoy, K. Nebulized Fentanyl in the Treatment of Dyspnea. Submitted, American Journal of Hospice and Palliative Medicine, 2005.
Shell, R. Vocal Cord Dysfunction: All That Wheezes is not Asthma. Columbus Parent, Supplement to The Columbus Dispatch, September, 2004.
Rosenfeld, M, Gibson, R, McNamara, S, Emerson, J, McCoy, K, Shell, R, Borowitz, D, Konstan, M, Tetsch-Bogart, G, Wilmott, R, Burns, J, Vicini, P, Ramsey, B. Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. J Pediatr 2001;139:572-7.
Shell, R, E. Allen, K. Mutabugani, F. Long, J.T. Davis, K. McCoy, R. Castile. Compression of the trachea by the innominate artery in a 2 month old child. Pediatric Pulmonology, 2001.
Sheikh, S, Allen, B, Shell, R,…Chronic Aspiration Without Gastroesophageal Reflux as a Cause of Chronic Respiratory Symptoms in Neurologically Normal Infants. Chest, 120, 2001.
Shell, R, McCoy, K. A New Century of Hope for Cystic Fibrosis and Gene Therapy. Pediatric Directions, Children’s Hospital, Columbus, Ohio. Winter 2000.
Jones, J, Shell, R. Cystic Fibrosis. Chapter 100. Applied Therapeutics, Inc. 1999
Zuckerman, J., C. Robinson, K. McCoy, R. Shell, T. Sferra, N. Chirmule, S. Magosin, K. Propert, J. Hughes, J. Tazelaar, C. Baker, M. Goldman, J. Wilson. A phase 1 study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Human Gene Therapy 10:2973-2985.

Research:

2005. Co-Investigator, Effectiveness and Safety of Intermittant Antimicrobial Therapy for the Treatment of New Onset Pseudomonas aeruginosa Airway Infection in Young Patients with Cystic Fibrosis. Cystic Fibrosis Therapeutic Development Network
2005. Co-Investigator, Evaluation of CF Patient Perception of Symptom Improvement Following Inhaled Antibiotic Treatment. Corus Pharma and Cystic Fibrosis Therapeutic Development Network
2005. Co-Investigator, A Multi-Center Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of Denufosol Tetrasodium (INS372217) Inhalation Solution in Patients with Cystic Fibrosis Lung Disease. Inspire Pharmaceuticals, Inc.
2005. Co-Investigator, CP-AI-005, A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial with Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients with Pulmonary P. aeruginosa. Corus Pharma and Cystic Fibrosis Therapeutic Development Network
2004. Principal Investigator, Standard Versus Biofilm Susceptibility Testing in Cystic Fibrosis CF Therapeutics Development Network, Children’s Hospital Research Center, Seattle, WA.
2004. Co-Investigator A Blinded, Multicenter, Randomized, Placebo-Controlled Trial with Aztreonam for Inhalation (AI) in Cystic Fibrosis Patients with Lung Disease Due to P. aeruginosa Infection. Salus Pharma Inc., Therapeutics Development Network
2004. Co-Investigator, The EPIC Observation study: Longitudinal Assessment of Risk Factors For and Impact of Pseudomonas aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children with CF. Therapeutics Development Network
2004. Co-Investigator, Assessment of Induced Sputum as a Tool to Evaluate Anti-Inflammatory Agents in Patients with Cystic Fibrosis. Cystic Fibrosis Foundation Therapeutics, Inc.
2003. Co-Investigator, A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of 24 weeks of oral treatment with BIIL 284 BS in adult (75 mg, 150 mg) and pediatric (75 mg) cystic fibrosis patients. Boehringer Ingelheim Pharmaceuticals, Inc.
2003. Co-Investigator, A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, 28-Day study of INS37217 Inhalation Solution in Subjects with Mild to Moderate Cystic Fibrosis Lung Disease. Inspire Pharmaceuticals, Inc.
2003-present. Co-Investigator, The Leukotriene Modifier of Corticosteroid or Corticosteroid-Salmeterol Trial (The LOCCS Trial). American Lung Association Asthma Clinical Research Center
2002. Co-Investigator, A Safety and Pharmacokinetic Assessment of Inhaled Administration of Moli1901 in Patients with Cystic Fibrosis. US Cystic Fibrosis Foundation Therapeutics, Inc.
2002. Co-Investigator, The Quest for Quality: Improving CF Outcomes. Ohio CF Consortium.
2002. Principal Investigator, A Stratified, Randomized, Double-Blind, Parallel-Group, 12-week Trial Evaluating the Safety and Efficacy of the Fluticasone Propionat/Salmeterol DISKUS Combination Product 100/50mcg BID Versus Fluticasone Propionate DISKUS 100mcg BID in Symptomatic Pediatric Subjects (4-11 Years) with Asthma Protocol: SAS30031, GlaxoSmithKline, PCTI, Children’s Hospital.
2002. Co-Investigator An Open –label Randomized Trial with Tobramycin Solution for Inhalation (TOBI) in Cystic Fibrosis Patients with Mild Lung Disease, Pathogenesis Corp., PCTI, Children’s Hospital
2002. Co-Investigator Duration of Antimicrobial Treatment Effect Following Administration of Tobramycin Solution for Inhalation (TOBI) in Young Children with Cystic Fibrosis, CF Therapeutics Development Network, Children’s Research Institute.
2002-present. Co-Investigator, Genetic Modifiers in Cystic Fibrosis Lung Disease (GMS). Case Western Reserve University
2001. Co-Investigator Massage Therapy in Children with Life Threatening Asthma. Children’s Research Institute
2001. Co-Investigator, A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Trial of Azithromycin in Patients with CF, Chronically Infected with Pseudomonas aeruginosa. US Cystic Fibrosis Foundation Therapeutics Inc.
2001-2003. Co-Investigator, Effectiveness of Low Dose Theophylline as Add-On Therapy in the Treatment of Asthma (The LoDo Trial). American Lung Association Asthma Clinical Research Center
2000. Co-Investigator A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial of the Safety of Inactivated Influenza Vaccine in Adults and Children with Asthma. ALA/ACRC.
Principal Investigator, Prevalence of Neutralizing Antibody to rAAV in Patients with Cystic Fibrosis, The Cystic Fibrosis Foundation and The Children’s Hospital Research Foundation
Co - Investigator, Gene Therapy for Cystic Fibrosis Lung Disease Using the Third Generation Adenovirus H5.001CBCCFTR: A phase 1 Trial. The University of Pennsylvania, The Ohio State University and The Children’s Hospital Research Foundation
Co - Investigator, Safety of Aerosolized Tobramycin (TOBI®) in Young Children with Cystic Fibrosis. Pathogenesis Corporation, The Cystic Fibrosis Foundation and The Children’s Hospital Research Foundation
Co-Investigator, A Pilot Study to Measure Lower Airway Deposition of Inhaled Tobramycin in Young Children with Cystic Fibrosis, The Cystic Fibrosis Foundation
Co-Investigator, Phase II, Prospective, Multicenter, Randomized, Double-Blinded, Age Stratified, Adjuvant-Controlled Trial of the Safety, Immunogenicity, and Effectiveness of the Intramuscularly Administered A248/404 Derived Respiratory Syncytial Virus Purified Fusion Protein (PFP-3) Vaccine against Lower Respiratory Tract Illness (LRTI) in Children with Cystic Fibrosis (CF) during the Respiratory Syncytial Virus (RSV) Season. CF Foundation, Wyeth Lederle Vaccines

Hospital Appointments:

Grants:

1998 - 1999. Research Grant, 3rd year fellowship, Cystic Fibrosis Foundation
1997 - 1998. Clinical Fellowship Training Grant, 2nd year fellowship, Cystic Fibrosis Foundation
1996 - 1997. Clinical Fellowship Training Grant, 1st year fellowship

Partial List of Presentations:

July, 2004. “Chronic Cough,” Otolaryngology Lecture Series, Columbus Children’s Hospital
July, 2004. “Asphyxiating Thoracic Dystrophy,” Orthopedic Grand Rounds, Columbus Children’s Hospital
October, 2003. “Pediatric Asthma Management,” Grand Rounds, Blanchard Valley Regional Health Center, Findley
2003. “Vocal Cord Dysfunction,” Lounge and Learn, Children’s Hospital
July 2002, 2003. “Inpatient management of asthma,” Emergency Lecture Series, Pediatric Residency Program, Children’s Hospital
April, 2002. "Interstitial lung disease,” Grand Rounds, Children’s Hospital
2002. "Asthma Management,” Riverside Family Practice Noon Lecture Series
December, 2001. “Pediatric Integrative Medicine,” Emergency Medicine Grand Rounds/Fellows Conference
September, 2001. “Asthma Update,” Pediatric Pearls: Sub-Specialty Update Course for Clinicians, Children’s Hospital, Columbus, Ohio
February, 2001. “Asthma Update,” AstraZeneca, Charelston and Beckley, West Virginia
September, 2000. "Complementary and Alternative Medicine in Pediatrics,” Pediatric Pearls, Children’s Hospital, Columbus, Ohio
August, 2000. “Outpatient Treatment of Asthma,” CORE lecture series, Doctor’s Hospital, Columbus, Ohio
April, 2000. “Asthma Update,” Invited Lecture, Fairfield Memorial Hospital, Lancaster, Ohio, Sponsored by AstraZenica.
October, 1999. “Pseudomembranous Colitis Complications in a Patient with Cystic Fibrosis,” North American Cystic Fibrosis Conference
September, 1999. “The Scope of Bronchoscopy in a Pediatric Hospital,” Children’s Hospital, Columbus, Ohio, Lounge and Learn Program
1998. “Prevalence of Neutralizing Antibody to rAAV in Patients with Cystic Fibrosis,” Children’s Hospital Research Forum, Presented with 3rd place.
1998. “A 53 year old Woman with Cough, Shortness of Breath and Weight Loss,” The Ohio Thoracic Society

Awards:

2007 Best Doctors in America®
2005. Excellence in Teaching Award, Department of Pediatrics, The Ohio State University
Listed, Best Doctor in America, 2004

Answers questions in the following forums:

Practice Address:

Education:

Licensure or Certification:

Associations:

Affiliations:

Partial List of Publications:

Research:

Hospital Appointments:

Grants:

Partial List of Presentations:

Awards:

Web Links: